Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Personalis Inc PSNL

Technology Scientific & Technical Instruments
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome... see more

Recent & Breaking News (NDAQ:PSNL)

CORRECTING and REPLACING Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

Business Wire February 22, 2021

Natera and Personalis Partner for Personalized Monitoring in Oncology

Business Wire February 17, 2021

Personalis to Present at Upcoming Investor Conferences

Business Wire February 16, 2021

Personalis to Report Fourth Quarter 2020 Financial Results on February 25, 2021

Business Wire February 11, 2021

Personalis Expands Leadership Team with Appointment of Susan Moriconi, VP of People and Chief Human Resources Officer

Business Wire February 8, 2021

Personalis to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

Business Wire February 4, 2021

Personalis Announces Pricing of Public Offering of Common Stock

Business Wire January 26, 2021

Personalis Announces Launch of Public Offering of Common Stock

Business Wire January 26, 2021

Personalis Reports Preliminary Fourth Quarter 2020 Revenue

Business Wire January 11, 2021

Personalis to Present at the 23rd Annual Needham Virtual Growth Conference

Business Wire December 28, 2020

Personalis Announces the Launch of NEOPS(TM), a Neoantigen-based Composite Biomarker for Cancer Immunotherapy Response

Business Wire December 17, 2020

Personalis Announces the Launch of SHERPA(TM) for High-Accuracy Neoantigen Prediction and Cancer Diagnostic Biomarker Development

Business Wire December 17, 2020

Personalis Announces Delivery of the 100,000th Genome to the U.S. Department of Veterans Affairs Million Veteran Program

Business Wire December 9, 2020

Personalis, Inc. to Present at EACR Liquid Biopsies Virtual Event

Business Wire November 18, 2020

Personalis® to Present at the AMP Annual Meeting 2020

Business Wire November 16, 2020

Personalis, Inc. to Present New Data at the Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting

Business Wire November 9, 2020

Personalis Reports Third Quarter 2020 Financial Results

Business Wire November 5, 2020

Personalis to Participate in Upcoming Investor Conferences

Business Wire October 27, 2020

Personalis to Announce Third Quarter 2020 Financial Results on November 5, 2020

Business Wire October 22, 2020

Personalis to Participate in Immuno Series US Virtual Meeting

Business Wire October 15, 2020